Developing novel treatments for mood disorders: Accelerating discovery

Carol A. Tamminga, Charles B. Nemeroff, Randy D. Blakely, Linda Brady, Cameron S. Carter, Kenneth L. Davis, Raymond Dingledine, Jack M. Gorman, Dimitri E. Grigoriadis, David C. Henderson, Robert B. Innis, John Killen, Thomas P. Laughren, William M. McDonald, Greer M. Murphy, Steven M. Paul, Matthew V. Rudorfer, Edward Sausville, Alan F. Schatzberg, Edward M. ScolnickTrisha Suppes

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder therapeutics is the topic of this article.

Original languageEnglish (US)
Pages (from-to)589-609
Number of pages21
JournalBiological Psychiatry
Volume52
Issue number6
DOIs
StatePublished - Sep 15 2002

Fingerprint

Mood Disorders
Consumer Advocacy
National Institute of Mental Health (U.S.)
Pharmacogenetics
Therapeutics
Neurosciences
Research
Industry
Central Nervous System

Keywords

  • Depression bipolar disorder research resources
  • Government/industry collaboration

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Tamminga, C. A., Nemeroff, C. B., Blakely, R. D., Brady, L., Carter, C. S., Davis, K. L., ... Suppes, T. (2002). Developing novel treatments for mood disorders: Accelerating discovery. Biological Psychiatry, 52(6), 589-609. https://doi.org/10.1016/S0006-3223(02)01470-1

Developing novel treatments for mood disorders : Accelerating discovery. / Tamminga, Carol A.; Nemeroff, Charles B.; Blakely, Randy D.; Brady, Linda; Carter, Cameron S.; Davis, Kenneth L.; Dingledine, Raymond; Gorman, Jack M.; Grigoriadis, Dimitri E.; Henderson, David C.; Innis, Robert B.; Killen, John; Laughren, Thomas P.; McDonald, William M.; Murphy, Greer M.; Paul, Steven M.; Rudorfer, Matthew V.; Sausville, Edward; Schatzberg, Alan F.; Scolnick, Edward M.; Suppes, Trisha.

In: Biological Psychiatry, Vol. 52, No. 6, 15.09.2002, p. 589-609.

Research output: Contribution to journalArticle

Tamminga, CA, Nemeroff, CB, Blakely, RD, Brady, L, Carter, CS, Davis, KL, Dingledine, R, Gorman, JM, Grigoriadis, DE, Henderson, DC, Innis, RB, Killen, J, Laughren, TP, McDonald, WM, Murphy, GM, Paul, SM, Rudorfer, MV, Sausville, E, Schatzberg, AF, Scolnick, EM & Suppes, T 2002, 'Developing novel treatments for mood disorders: Accelerating discovery', Biological Psychiatry, vol. 52, no. 6, pp. 589-609. https://doi.org/10.1016/S0006-3223(02)01470-1
Tamminga, Carol A. ; Nemeroff, Charles B. ; Blakely, Randy D. ; Brady, Linda ; Carter, Cameron S. ; Davis, Kenneth L. ; Dingledine, Raymond ; Gorman, Jack M. ; Grigoriadis, Dimitri E. ; Henderson, David C. ; Innis, Robert B. ; Killen, John ; Laughren, Thomas P. ; McDonald, William M. ; Murphy, Greer M. ; Paul, Steven M. ; Rudorfer, Matthew V. ; Sausville, Edward ; Schatzberg, Alan F. ; Scolnick, Edward M. ; Suppes, Trisha. / Developing novel treatments for mood disorders : Accelerating discovery. In: Biological Psychiatry. 2002 ; Vol. 52, No. 6. pp. 589-609.
@article{c7c6adf42729491e9a7d819a5436adbf,
title = "Developing novel treatments for mood disorders: Accelerating discovery",
abstract = "This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder therapeutics is the topic of this article.",
keywords = "Depression bipolar disorder research resources, Government/industry collaboration",
author = "Tamminga, {Carol A.} and Nemeroff, {Charles B.} and Blakely, {Randy D.} and Linda Brady and Carter, {Cameron S.} and Davis, {Kenneth L.} and Raymond Dingledine and Gorman, {Jack M.} and Grigoriadis, {Dimitri E.} and Henderson, {David C.} and Innis, {Robert B.} and John Killen and Laughren, {Thomas P.} and McDonald, {William M.} and Murphy, {Greer M.} and Paul, {Steven M.} and Rudorfer, {Matthew V.} and Edward Sausville and Schatzberg, {Alan F.} and Scolnick, {Edward M.} and Trisha Suppes",
year = "2002",
month = "9",
day = "15",
doi = "10.1016/S0006-3223(02)01470-1",
language = "English (US)",
volume = "52",
pages = "589--609",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Developing novel treatments for mood disorders

T2 - Accelerating discovery

AU - Tamminga, Carol A.

AU - Nemeroff, Charles B.

AU - Blakely, Randy D.

AU - Brady, Linda

AU - Carter, Cameron S.

AU - Davis, Kenneth L.

AU - Dingledine, Raymond

AU - Gorman, Jack M.

AU - Grigoriadis, Dimitri E.

AU - Henderson, David C.

AU - Innis, Robert B.

AU - Killen, John

AU - Laughren, Thomas P.

AU - McDonald, William M.

AU - Murphy, Greer M.

AU - Paul, Steven M.

AU - Rudorfer, Matthew V.

AU - Sausville, Edward

AU - Schatzberg, Alan F.

AU - Scolnick, Edward M.

AU - Suppes, Trisha

PY - 2002/9/15

Y1 - 2002/9/15

N2 - This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder therapeutics is the topic of this article.

AB - This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder therapeutics is the topic of this article.

KW - Depression bipolar disorder research resources

KW - Government/industry collaboration

UR - http://www.scopus.com/inward/record.url?scp=0037106951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037106951&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(02)01470-1

DO - 10.1016/S0006-3223(02)01470-1

M3 - Article

C2 - 12361670

AN - SCOPUS:0037106951

VL - 52

SP - 589

EP - 609

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 6

ER -